The company’s inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, will enter phase 1/2, they announced today.
Valneva will use a randomised, double-blind study to test the vaccine, taking place in several sites across the UK.
Although encouraging, vaccine chiefs said it would take much longer to develop than others in the US and UK.
They said not to expect an “initial regulatory approval” until the “fourth quarter” of 2021.